Suppr超能文献

挽救性立体定向体部放疗治疗其他局部治疗后复发/残留肝细胞癌的局部控制。

Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies.

机构信息

Radiation Oncology Center, Ofuna Chuo Hospital, Kamakura, Japan.

Department of Radiation Oncology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan.

出版信息

Acta Oncol. 2020 Aug;59(8):888-894. doi: 10.1080/0284186X.2020.1741679. Epub 2020 Mar 27.

Abstract

To clarify local control by salvage stereotactic body radiotherapy (SBRT) for recurrent/residual hepatocellular carcinoma (HCC) compared with initial definitive SBRT for local treatment-naïve HCC. We retrospectively investigated HCC patients that received SBRT between July 2005 and December 2017. We classified HCC tumors as the initial definitive SBRT group (Arm-1; initial definitive SBRT, Arm-2; initial definitive planned SBRT following transarterial chemoembolization (TACE)) and salvage SBRT group (Arm-3; salvage SBRT for recurrent/residual tumors after TACE, Arm-4; salvage SBRT for recurrent/residual tumors after radiofrequency ablation (RFA), Arm-5; salvage SBRT for recurrent/residual other than Arm-3 or Arm-4). Local control was evaluated by mRECIST. We reviewed 389 HCC tumors of 323 patients treated by 35-40 Gy/5 fr. The median follow-up time for local recurrence of tumors was 34.8 months (range, 6.5-99.2). The cumulative local recurrence rates at 3 years of Arm-1-5 were 1.4% (95% CI, 0.3-4.4%), 5.0% (95% CI, 1.6-11.5%), 12.4% (95% CI, 5.7-21.9%), 14.8% (95% CI, 3.3-34.3%) and 7.3% (95% CI, 1.9-18.0%), respectively. The cumulative local recurrence rates at 3 years of initial definitive treatment and salvage treatment groups were 2.8% (95% CI, 1.1-5.6%) and 11.1% (95% CI, 6.3-17.3%), respectively (=.004). On multivariate analysis, salvage treatment and the tumor diameter were significant risk factors of local recurrence ( = .02,  < .001 respectively). Estimated overall survival at 3 years for all patients in initial definitive treatment and salvage treatment groups were 71.5% (95% CI, 63.4-78.1%) and 66.1% (95% CI, 56.4-74.2%), respectively ( = .20). No treatment-related death caused by SBRT was observed. This analysis showed local control of salvage SBRT for recurrent/residual HCC was significantly worse than that of initial definitive SBRT for local treatment-naïve HCC. However, local control of salvage SBRT was relatively good, and salvage SBRT is one of the favorable treatment options for recurrent/residual HCC.

摘要

为了明确挽救性立体定向体放射治疗(SBRT)治疗复发性/残留肝细胞癌(HCC)的局部控制情况,与局部治疗初治的 HCC 初始确定性 SBRT 相比。我们回顾性研究了 2005 年 7 月至 2017 年 12 月期间接受 SBRT 的 HCC 患者。我们将 HCC 肿瘤分为初始确定性 SBRT 组(Arm-1;初始确定性 SBRT、Arm-2;初始确定性计划 SBRT 后经动脉化疗栓塞术(TACE))和挽救性 SBRT 组(Arm-3;TACE 后复发性/残留肿瘤的挽救性 SBRT、Arm-4;射频消融(RFA)后复发性/残留肿瘤的挽救性 SBRT、Arm-5;除 Arm-3 或 Arm-4 之外的其他复发性/残留肿瘤的挽救性 SBRT)。局部控制通过 mRECIST 评估。我们回顾了 323 名患者的 389 个 HCC 肿瘤,接受了 35-40Gy/5fr 的治疗。肿瘤局部复发的中位随访时间为 34.8 个月(范围 6.5-99.2)。Arm-1-5 组的 3 年累积局部复发率分别为 1.4%(95%CI,0.3-4.4%)、5.0%(95%CI,1.6-11.5%)、12.4%(95%CI,5.7-21.9%)、14.8%(95%CI,3.3-34.3%)和 7.3%(95%CI,1.9-18.0%)。初始确定性治疗和挽救性治疗组的 3 年累积局部复发率分别为 2.8%(95%CI,1.1-5.6%)和 11.1%(95%CI,6.3-17.3%)(=0.004)。多变量分析显示,挽救性治疗和肿瘤直径是局部复发的显著危险因素(=0.02,<0.001)。所有患者在初始确定性治疗和挽救性治疗组的 3 年总生存率分别为 71.5%(95%CI,63.4-78.1%)和 66.1%(95%CI,56.4-74.2%)(=0.20)。未观察到因 SBRT 引起的治疗相关死亡。本分析显示,复发性/残留 HCC 挽救性 SBRT 的局部控制明显差于局部治疗初治的 HCC 初始确定性 SBRT。然而,挽救性 SBRT 的局部控制相对较好,挽救性 SBRT 是复发性/残留 HCC 的一种有利治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验